Epithelial-mesenchymal transition (EMT) is an evolutionarily conserved cellular program, which is a prerequisite for the metastatic cascade in carcinoma progression. Here, we evaluate the EMT process using the sea urchin Paracentrotus lividus embryo. In sea urchin embryos, the earliest EMT event is related to the acquisition of a mesenchymal phenotype by the spiculogenetic primary mesenchyme cells (PMCs) and their migration into the blastocoel. We investigated the effect of inhibiting the epidermal growth factor (EGF) signaling pathway on this process, and we observed that mesenchyme cell differentiation was blocked. In order to extend and validate our studies, we investigated the migratory capability and the level of potential epidermal growth factor receptor (EGFr) targets in a breast cancer cell line after EGF modulation. Altogether, our data highlight the sensitivity of the sea urchin embryo to anti-EMT drugs and pinpoint the sea urchin embryo as a valuable in vivo model system for studying EMT and the screening of anti-EMT candidates.
Introduction
Epithelial-mesenchymal transition (EMT) is a specific cellular process in which the typical epithelial architecture changes into a mesenchymal phenotype. This cellular change occurs through different processes, such as the loss of cell-cell contacts (i.e., adherens junctions, desmosomes, and tight junctions) and a corresponding increase in migratory abilities. EMT plays a fundamental physiological role during embryo development and in certain pathological conditions, such as metastatic carcinoma (Thiery et al. 2009; Lim & Thiery 2012) .
The development of a high-to medium-throughput, low-cost in vivo system to screen for bioactive molecules inhibiting EMT would be ideal for developing antimetastatic drugs. To date, limited cellular and in vivo models have been developed to study the molecular mechanisms and signaling pathways involved in EMT (Eger & Mikulits 2005; Giuriato et al. 2006; Bae et al. 2012; Chua et al. 2012) . The major limitation of the cellular system is that EMT is experimentally induced by the addition of specific growth factors, and this limits the analyses to certain cellular signals.
The epidermal growth factor (EGF) pathway performs an important role in the EMT process and metastasis (Thiery et al. 2009 ). Among other effects, this signaling produces an increase in the expression of the Slug and/or Twist transcription factors and, consequently, the transcriptional repression of E-Cadherin expression and a loss of adherens junctions (Hajra et al. 2002; Conacci-Sorrell et al. 2003; Kusewitt et al. 2009 ).
Here, we have established an in vivo assay based on sea urchin development and analyzed the effect of EGFr inhibition on the physiological EMT process using the bioactive molecule Tyrphostin AG1478 (an EGFr phosphorylation inhibitor). Furthermore, after AG1478 treatments in sea urchin embryos, we have analyzed the expression pattern of two members of the Snail superfamily of transcription factors: Snail, playing an important role in PMC ingression , and ScratchX/Snai2. In order to extend and validate our in vivo results, we used highly metastatic MDA-MB-231 breast cancer cells. EGFr inhibition by AG1478, the migratory capacity and EGF downstream pathway/s were evaluated.
Materials and methods
Sea Urchin-based in vivo EMT assay Paracentrotous lividus sea urchins were collected along the northwestern coast of Sicily, Italy. The location where the sea urchins were collected is public, and only a limited number of specimens (<50) were collected, by a professional fisherman, during the permitted fishing season. No specific permits were required for this activity. Sea urchins were transported to the "MarLab", a research laboratory at the Institute of Biomedicine and Molecular Immunology (IBIM) of the CNR of Palermo, designed, organized and managed according to a Quality Management System (QMS) (quality certification UNI ISO 9001:2008 #585SGQ00). Sea urchins were maintained in tanks and fed kelp ad libitum for 10 days to acclimate the natural cycle until used in experiments. Eggs were harvested, fertilized with fresh diluted sperm and cultured at 18°C as previously described (Sconzo et al. 1995) .
For the EMT assays, AG1478 (Sigma) was added to fertilized eggs (FE) or hatched blastulae (HB, 11 h postfertilization) at 1, 5, 10, 20 lmol/L final concentration; dimethyl sulfoxide (DMSO) was used as control at 0.02% (v/v) final concentration. We used 24-well plates (not TC-treated) with 300 embryos each. When control embryos reached the mesenchyme blastula stage (up to 15 h following fertilization), samples were fixed and microscopically analyzed or stained for specific antigens. Each experimental condition was replicated in two wells, images of three different optical fields were taken, and the morphotype of at least 100 embryos/ well was analyzed. Experiments were repeated three times using different batches of gametes. To assess that the aberrant morphotype was not a consequence of a delay in development, embryos were observed up to 19 h. In these experiments, the percentage of aberrant morphotypes did not change significantly. For TGFa rescue experiments 20, 40 or 80 ng/mL TGFa (PeproTech) was added together with 10 lmol/L AG1478 at FE or HB stage in EMT assays using same experimental condition, as described above. Embryos were allowed to develop up to pluteus stage (58 h postfertilization) and after fixation, photographed using a Leica DM IL inverted microscope.
Quantitative PCR
Reverse-transcription and qPCR analyses were performed as described (Romancino et al. 2013) . Briefly, control and AG1478 treated embryos were grown in a 6 well non-treated plate (5.000 embryos/mL). Total RNA was extracted using TRI Reagent (Sigma-Aldrich), according to the manufacturer's instructions, and after DNAseI treatment, purified by phenol/chloroform extractions. RNA concentration was estimated by fluorescence-based Qubit quantitation assays in a Qubit 2.0 Fluorometer (Invitrogen).
Samples were retro-transcribed with SuperScript III Reverse Transcriptase (Invitrogen) using 1.5 lg of RNA. Quantitative real-time polymerase chain reaction (qPCR) was carried out on the cDNA equivalent of 6 embryos (20 ng) using Power SYBR Green Master Mix (Applied Biosystems). Snail and ScratchX/Snai2 specific primers were derived from P. lividus cDNAs; the amplicon lengths were 106 and 136 bp, respectively:
Pl-Z12-1 was used as endogenous control (Costa et al. 2012) , with the following primers:
qPCR experiments were carried out in triplicate using StepOnePlus Real-Time PCR System (Applied Biosystems); data were analyzed with the comparative C t method (ΔΔC t ). PCR cycle conditions were: 95°C for 10 min, followed by 40 cycles (95°C for 15 s and 60°C for 1 min) and a final melting curve step.
Cell culture and wound healing assay
The MDA-MB-231 human breast cancer cell line (ATCC, HTB-26, Manassas, VA, USA) was maintained in Dulbecco's Modified Eagle Medium (DMEM) medium supplemented with 10% fetal calf serum, 2 mmol/ L glutamine, and antibiotics (100 U/mL penicillin and 0,1 mg/mL streptomycin). For the wound healing assay MDA-MB-231 cells were grown subconfluent, and a wound was made by scratching cells with a sterile 200 lL micropipette tip. Cells were washed twice and incubated in the presence of 0.02% (v/v) DMSO as control, 20 lmol/L AG1478 and EGF (100 ng/mL). After being cultured for 24 h, cell migration into the wound was observed and photographed with an inverted microscope (Leica DM IL). The result was quantified by measuring the distance of the gap between the edges of the scratch at the time of scratching (time 0 h) and at 24 h in 5 independent fields per condition. The average rate of wound closure was calculated as percentage.
Protein extracts from MDA-MB-231 cells and Immunoblot
Cytoplasmic, membrane/organelle, nuclear, and cytoskeletal fractions were prepared using the ProteoExtract subcellular proteome extraction kit (Calbiochem, Merck), according to the manufacturer's instructions. To obtain total protein extracts, cells were lysed in RIPA buffer [50 mmol/L Tris-HCl (pH7.4), 1% NP-40, 0.5% Sodium deoxycholate, 0.1% Sodium dodecyl sulfate, 150 mmol/L NaCl supplemented with protease and phosphatase inhibitor]. Aliquots of proteins (30 lg) from subcellular fractionation and RIPA extracts were loaded onto sodium dodecyl sulfate (SDS) 8-16% precast polyacrylamide gel (Thermo Scientific) and subjected to electrophoresis. Proteins were wet transferred onto polyvinylidene difluoride membranes (Immobilon-FL; Merck, Millipore), then stained with Ponceau S solution (Sigma), used as a loading control. Immunoblotting was performed using Odyssey blocking buffer (LI-COR Biosciences), and primary antibodies were rabbit anti-Dsg2 (H-145, Santa Cruz Biotechnology) diluted 1:200 and mouse anti-Slug (A-7, Santa Cruz Biotechnology) diluted 1:200. Secondary antibodies were Alexa Fluor 680 goat anti-rabbit diluted 1:5000 (Molecular Probes, Life Technologies) and goat anti-mouse IRDye 800 diluted 1:3000 (LI-COR Biosciences). The quantification of bands was carried out using the Odyssey Infrared Imaging System (LI-COR Biosciences). All data are normalized to the corresponding total protein amount, based on Ponceau S stain, and are expressed as a percentage of protein expression, relative to the corresponding DMSO control, set at 100%.
Immunofluorescence
Whole-mount embryos were fixed and stained as previously described (Romancino et al. 2008) . Immunostaining was performed with an anti-msp130, which recognizes a mesenchyme specific antigen (kind gift of Professor D.R. McClay), and FITC-wheat germ agglutinin (SIGMA). Alexa Fluor 594 anti-mouse IgG (Invitrogen) was used as secondary antibody.
MDA-MB-231 cells were fixed in 4% paraformaldehyde, blocked with 3% bovine serum albumin, permeabilized with 0.2% Triton X-100 when immunostained with anti-Slug (A-7, diluted 1:200), and not permeabilized when immunostained with anti-Dsg2 (H-145, diluted 1:200). Alexa Fluor 594 anti-rabbit IgG (Invitrogen) and Alexa Fluor 488 anti-mouse IgG (Invitrogen) were used as secondary antibodies, diluted 1:500 and 1:300 respectively. Epifluorescence images were acquired using an Axioskop-2 plus microscope (Zeiss).
Statistical analyses
Each experiment was performed at least three times. Data were expressed as mean AE standard deviation (SD) and were evaluated using Student's t-test. Mean differences were considered statistically significant when P values were <0.05 (*).
Results and discussion
A sea urchin in vivo model to evaluate the effect of EGFr inhibition on EMT Embryos of the sea urchin Paracentrotus lividus have long been used as a multipurpose model organism for different studies in a variety of fields, ranging from embryology to developmental toxicology (Giudice 1973; Sconzo et al. 1995) . The first morphological evidence of EMT in sea urchin embryo development is the ingression of primary mesenchyme cells (PMCs). Ingression consists of a complex, precisely-timed modulation of cell-cell and cell-matrix adhesions that results in the migration of PMCs from the vegetal plate of the blastula embryo into the blastocoel Katow 2015) . In the P. lividus embryo maintained at 18°C, EMT begins at 11 and is completed about 15 h after fertilization, when mesenchyme blastulae show a characteristic ring-shaped positioning of mesenchyme cells vegetally located inside the embryo.
The sea urchin embryo is a highly valuable model to detect both phenotypic and molecular changes after the addition of chemical agents. Drugs can be easily added to the culture at any time of development, revealing specific mechanisms and identifying molecular targets. To analyze the sensitivity of the sea urchin embryo towards a known modulator of tumor-related EMT, the bioactive molecule Tyrphostin AG1478, we developed an efficient and reproducible in vivo assay based on the evaluation of the presence/absence or specification of the primary mesenchyme cells (PMCs) in mesenchyme blastula stage embryos (Fig. 1a) .
The experimental set-up was the following: P. lividus embryos at the zygote (FE, just after fertilization) or hatching blastula (HB, 11 h postfertilization and prior to PMC ingression) stages were incubated in the presence of different concentrations of AG1478 (Fig. 1a) ; the effects were evaluated 15 h postfertilization, when almost 100% of the embryos in the control sample were late mesenchyme blastulae (Fig. 1b, panel A) . These two developmental stages (FE and HB) were chosen to allow the inhibition of either early (at FE) or late (at HB) signals that induce embryonic EMT. Adding AG1478 at the fertilization stage provides information about all the early (PMC commitment) and late (leading to the acquisition of a migratory phenotype and PMC specification) pathways involved in EMT. These include early signals such as Wnt, b-catenin nuclearization in micromeres, and the Erk pathway (Logan et al. 1999; Rottinger et al. 2004; Romancino et al. 2008; Range et al. 2013) . In contrast, adding the drug at the hatching blastula stage furnishes specific information about later signals and mechanisms related to the detachment of PMCs from the blastula epithelium and their migration .
When embryos were treated with AG1478 at the HB stage, we observed the appearance of blastulae in which the blastocoel was filled with a high number of cells arranged in a disorganized manner, (8.5-34%, depending on the AG1478 concentration). We named them occluded blastulae (Fig. 1b , panels B and D; Fig.1c and d) . When we added AG1478 at fertilization, we observed an increase in the number of occluded blastulae, ranging from 6.5% (1 lmol/L) to 65% (20 lmol/L) (Fig. 1d) . It must be noted that AG1478 amounts higher than 10 lmol/L led to a large number of degenerated embryos, 20% and 35%, when AG1478 was added at HB and FE, respectively (Fig. 1b , panels B and E; Fig. 1c and d) . These embryos were immobile and prone to dissociation. On the contrary, the occluded blastulae were alive and actively swimming. When we co-treated with AG1478 and TGFa, a canonical ligand of EGFr (Schlessinger 2002; Singh & Coffey 2014) , at fertilization or hatching blastula stage, embryonic phenotype was efficiently rescued, confirming that effect of AG1478 was specific, and not merely a toxic side-effect (Fig. S1) . Thus, we can conclude that, in our experimental condition, AG1478 inhibits an EGFr related pathway, and TGFa is able to revert embryos to a normal pluteus phenotype (Fig. S1 ). This evidence is in line with and extends previous findings (Romancino et al. 2008) .
To characterize the nature of the cells within the blastocoel of the occluded blastulae, we performed et al. 1987; Miller et al. 1995) . In AG1478-treated embryos, all cells of the occluded blastulae were negative for both markers (Fig. 2a panels F -J, embryo indicated by arrow), while control and normal embryos of AG1478-treated samples showed proper staining for both WGA and msp130 antigen in primary mesenchyme cells (Fig. 2a panels A-E and F-J, embryo indicated by arrowhead). This evidence shows the absence of mesenchymal cells inside the occluded blastulae after EGFr inhibition. We previously have shown the presence of a similar phenotype (occluded blastulae) following treatment with AG1478 from fertilization up to the 7 th cleavage stage (5 h postfertilization), a period when very early events related to EMT occur. Later in development, after 48 h when control embryos were at pluteus stage, their blastocoels were filled with cells of nonmesenchymal origin (Romancino et al. 2008) . Differently, the appearance of occluded blastulae in our present study demonstrate that an effective inhibition of EMT is also elicited when the drug is administered to hatching blastula stage embryos, about 6 h after the 7th cleavage (11 h postfertilization), a time when late events related to EMT occur. This last result suggests that the EGFr activity is necessary even for late signals leading to EMT induction. In line with these findings, it has been shown that EMT requires multiple and parallel regulatory inputs in the sea urchin embryo, each of them functioning in a non-overlapping series of sub-circuits that act at different developmental times, and also immediately before and after EMT (Saunders & McClay 2014) . EGFr in sea urchins is encoded by a single copy gene, and is expressed throughout development (Lapraz et al. 2006; Romancino et al. 2008) . To evaluate if EGFr inhibition perturbed the expression of transcription factors activated proximal to EMT we have focused on Snail superfamily members. These protein members are characterized by a N-terminal SNAG domain and five C2H2-type zinc-fingers at the carboxytermini (Nieto 2002; Materna et al. 2006) . By cDNA isolation and in silico analysis of P. lividus databases, we have identified the P. lividus Snail and ScratchX/Snai2 (Accession nr. LT821716 and LT558581, respectively). Amino acid comparison of P. lividus Snail and ScratchX/Snai2 evidently revealed that they are two distinct members of the Snail superfamily (34% identity and 45% similarity each other). This evidence was confirmed by cDNA sequence alignment along both the coding and untranslated regions (not shown). Snail is highly conserved in three sea urchin species (Wu & McClay 2007 and our unpublished data) . Sequence comparison of P. lividus ScratchX/Snai2 with the human SLUG allowed us to recognize a canonical SNAG domain, and five highly conserved zinc-fingers motifs. In addition, we recognized a small sequence localized in the central part of the sea urchin ScratchX / Snai2, showing 29% identity and 53% similarity with the human Slug domain.
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Paracentrotus lividus embryos were incubated for 15 h from fertilization with 10 lmol/L AG1478, or for 4 h at hatching blastula stage with 10, 15 or 20 lmol/ L AG1478. RNAs were extracted when control embryos reached the mesenchyme blastula stage (15 h after fertilization). Snail and ScratchX/Snai2 transcript levels were determined by quantitative PCR analyses.
Paracentrotus lividus Snail and ScratchX/Snai2 are both expressed at very low levels during cleavage stages, and their expression increases at post-hatching developmental stages , and our unpublished data).
As shown in Figure 2b , EGFr inhibition by 10 lmol/L AG1478 from fertilization up to mesenchyme blastula stage caused a decrease of Snail expression (42%). The inhibitory effect on ScratchX/Snai2 transcript levels was even stronger (74%). As expected, the same treatment applied to the hatched blastulae produced fewer occluded blastulae and a lower decrease of Snail and ScratchX/Snai2 expression (26% and 56% respectively). Notably, HB stage treatment with 10, 15 or 20 lmol/L AG1478 inhibited the expression of both Snail and ScratchX/Snai2 with a dose dependent effect (Fig. 2b) . These data show that during sea urchin development Snail and ScratchX/Snai2 expression is regulated by EGFr, and that EGF signaling exerts a more marked effect on the family member ScratchX /Snai2.
Snail superfamily members play a crucial role in initiating EMT; Slug in chick embryos and Snail in mouse are involved in the detachment and migration of epithelial cells from neural crest and mesoderm (Sefton et al. 1998) . Notably, Slug and Snail transcription factors perform their activity through repression of E-cadherin expression, thereby transforming normal epithelial cells into mesenchymal cells (Hajra et al. 2002; Nieto 2002; Bolos et al. 2003) . Lytechinus variegatus Snail is expressed in the vegetal region of the hatched blastulae and then in the ingressing PMCs. It has been shown that Snail acts downstream of early micromere specification, and is required for PMC ingression .
Altogether, our results point to a critical role of EGFr in controlling sea urchin PMC specification and embryonic EMT, suggesting a role for Snail and ScratchX/ Snai2 in this process. However, future functional studies will clarify the ScratchX/Snai2 specific function.
In summary, these results show the high sensitivity of the sea urchin embryo in vivo assay for the screening of anti-EMT candidates.
EGFr modulation influences breast cancer cell migration
To corroborate and extend the results of our sea urchin embryo-based EMT assays, we subsequently evaluated cell migration activity in the MDA-MB-231 metastatic breast cancer cell line, following the modulation of EGFr using AG1478.
As reported in the sea urchin embryo, treatments carried out with 20 lmol/L AG1478 induced a significant number of occluded blastulae, which were negative for mesenchymal markers; this dose is not toxic for the mammalian cell line (Zhang et al. 2008) . Subconfluent MDA-MB-231 cells were subjected to wound healing assays and treated with AG1478, EGF, or ª 2017 Japanese Society of Developmental Biologists DMSO as control. 24 h after treatment with AG1478, we observed a significant modification of the typical fibroblastic, spindle-shaped morphology into epithelial clusters and a concomitant reduction of migrating cells on the denuded zone between the wound edges compared to control and the EGF-treated cells (Fig. 3a, b and c).
EGFr modulation and potential downstream targets: Slug, Desmoglein-2 and Vimentin
To analyze the expression levels of specific EMT markers and potential EGFr downstream targets (Katafiasz et al. 2011; Variluoto et al. 2011; Kume et al. 2013) , Slug, Desmoglein-2, and Vimentin immunoblots were performed from subcellular fractionations or total protein extracts of MDA-MB-231 cells treated with AG1478, EGF, or DMSO as control. Immunoblots of total protein extracts were first analyzed with antiVimentin polyclonal antibody. Band quantification from western blots revealed equal amounts of Vimentin in all the extracts analyzed compared to the relative Ponceau stainings (Fig. 3d, e) . Vimentin, an intermediate filament protein, is present in cells of mesenchymal origin (Steinert & Roop 1988) . Vimentin expression modulates migration and induces EMT in the nontransformed breast epithelial cells MCF10A (Variluoto et al. 2011) . MDA-MB-231 cells expressed high levels of Vimentin, and this could explain why we could evaluate only slight differences of Vimentin level following EGFr modulation.
Slug, was expressed at similar levels in cytosol after the different treatments; in contrast its expression in nuclear fractions was significantly higher after EGF induction, and it sharply decreased after AG1478 treatment, compared to controls (Fig. 3f, g ). As demonstrated in other mammalian cell systems, the transcription factor Slug acts as a repressor of the gene expression of different cell adhesion proteins, such as E-cadherin, Desmoglein-2 and 3, Desmocollin-2, and plakophilin-1 (Hajra et al. 2002; Conacci-Sorrell et al. 2003; Kurrey et al. 2005; Katafiasz et al. 2011) .
Desmoglein-2 is a glycoprotein found in desmosomes, at cell-cell junctions, and expressed in epithelia, and myocardium, where contributes to cell adhesion (Schafer et al. 1994) . Desmoglein-2 degradation is related to a decrease of cell adhesion, increase of migration and invasion, and is fine tuning regulated by EMT marker Snail in oral squamous cell carcinoma cells (Kume et al. 2013) . In line with this, the Desmoglein-2 level increased significantly in the membrane/organelle and cytoskeleton fractions treated with AG1478 (Fig. 3f, h) . Similarly, the SKOV3 ovarian cancer cell line, expressing exogenous Slug, has a reduced Desmoglein-2 expression, and shows induction of the EMT process (Kurrey et al. 2005) . Furthermore, Slug overexpression in head and neck squamous carcinoma cells (UM-SCC-38) leads to altered desmosome assembly with the reduced expression of desmosomal proteins, such as Desmoglein-3, Desmocollin-2 and plakophilin-1 (Katafiasz et al. 2011) . Although it has been reported that Slug binds E-box consensus sequences in the E-cadherin promoter and represses E-cadherin expression at the transcriptional level (Bolos et al. 2003) , nothing is known about the effect of Slug on Desmoglein-2 expression. Thus, to evaluate a possible direct effect of Slug on Desmoglein-2 expression, we began to analyze in silico the promoter region of the human Desmoglein-2 gene. We downloaded this promoter region from the Eukaryotic Promoter Database (EPDnew, http://epd.vital-it.ch/) and inspected it using the TFSEARCH program (Yutaka Akiyama: "TFSEARCH: Searching Transcription Factor Binding Sites", http:// www.rwcp.or.jp/papia) (Dreos et al. 2013) . The analysis showed that the promoter region of the human Desmoglein-2 gene (-499 to 100 bp) contains two putative E-box sequences (CAGGTG, -233 to -228 bp, and CACCTG, -117 to -112 bp) that can potentially serve as Slug binding elements.
Immunofluorescence analyses of untreated MDA-MB-231 cells showed that Desmoglein-2 was mainly present within the cells and was rarely seen at cell-cell contacts, even though it was observed in some epithelial clusters in controls ( Fig. 4a and a' ). This intracellular localization was probably a result of Desmoglein-2 internalization in metastatic MDA-MB-231 cells (Klessner et al. 2009 ), as also borne out by the higher number of Desmoglein-2-positive intracellular puncta in the control cells compared to AG1478-treated cells (Fig. 4a and a' versus b and b' ). In AG1478-treated cells, Desmoglein-2 was found in larger amounts at cell-cell contacts compared to control cells ( Fig. 4b and b' ). In contrast, EGF treatment produced fewer cell aggregates and lower levels of Desmoglein-2 in the cells, compared to control and AG1478-treated cells (Fig. 4c) . As confirmation of the immunoblot analyses, the level of Slug, was lower following the inhibition of EGFr (Fig. 4e and e') compared to control (Fig. 4d and d' ) and EGF-treated cells (Fig. 4f) . Slug decrease in human breast adenocarcinoma cells as an effect of AG1478 paralleled the reduction of ScratchX/Snai2 transcription levels previously described in the vivo sea urchin model. In summary, our results from both the in vivo and the cellular EMT systems reveal an impairment of both embryonic and tumor-related EMT processes in response to the inhibition of EGFr. We highlight that ª 2017 Japanese Society of Developmental Biologists ª 2017 Japanese Society of Developmental Biologists EGF signaling is connected to early and late events related to EMT in the sea urchin embryo model, and suggest that both Snail and ScratchX/Snai2 are key molecular signals involved in EGF-related EMT. In parallel, we show that Slug downregulation is associated to EGFr-related EMT and positively modulated Desmoglein-2 level, in the cellular model. The sea urchin embryo represents a robust and recognized model system to evaluate morphological changes after exposure to external stimuli and to elucidate evolutionarily conserved developmental processes. In this study, we point to the strength and feasibility of our sea urchin embryo based assay to test new bioactive molecules affecting EMT and for screening of anti-EMT candidates.
